S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

Withdrawn before enrolling · Phase 2

Conditions studied: Lymphoma

In brief

RATIONALE: Sometimes the cancer may not need treatment until it progresses. In this case, observation may be sufficient. Giving combination chemotherapy together with bortezomib, thalidomide, and rituximab before an autologous peripheral stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as G-CSF, helps stem cells move from the bone marrow to the blood so they can be collected and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. PURPOSE: This observational and phase II trial is studying how well giving combination chemotherapy together with bortezomib, thalidomide, and rituximab followed by two autologous peripheral blood stem cell transplants works in treating patients with Waldenstrom macroglobulinemia.

Key facts

Study ID

NCT00723658

Run by

SWOG Cancer Research Network

People needed

0

Starts

2008-09-01

Last updated by the study team

2015-03-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center — Hartford, Connecticut, United States
• St. Francis Hospital and Health Centers - Beech Grove Campus — Beech Grove, Indiana, United States
• Reid Hospital & Health Care Services — Richmond, Indiana, United States
• Lawrence Memorial Hospital — Lawrence, Kansas, United States
• Wesley Medical Center — Wichita, Kansas, United States
• Saint Joseph Mercy Cancer Center — Ann Arbor, Michigan, United States
• CCOP - Michigan Cancer Research Consortium — Ann Arbor, Michigan, United States
• Oakwood Cancer Center at Oakwood Hospital and Medical Center — Dearborn, Michigan, United States
• Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
• Genesys Hurley Cancer Institute — Flint, Michigan, United States
• Hurley Medical Center — Flint, Michigan, United States
• Van Elslander Cancer Center at St. John Hospital and Medical Center — Grosse Pointe Woods, Michigan, United States
• Foote Memorial Hospital — Jackson, Michigan, United States
• Sparrow Regional Cancer Center — Lansing, Michigan, United States
• St. Mary Mercy Hospital — Livonia, Michigan, United States
• St. Joseph Mercy Oakland — Pontiac, Michigan, United States
• Mercy Regional Cancer Center at Mercy Hospital — Port Huron, Michigan, United States
• Seton Cancer Institute at Saint Mary's - Saginaw — Saginaw, Michigan, United States
• St. John Macomb Hospital — Warren, Michigan, United States
• Grandview Hospital — Dayton, Ohio, United States
• Good Samaritan Hospital — Dayton, Ohio, United States
• David L. Rike Cancer Center at Miami Valley Hospital — Dayton, Ohio, United States
• CCOP - Dayton — Dayton, Ohio, United States
• Blanchard Valley Medical Associates — Findlay, Ohio, United States
• Middletown Regional Hospital — Franklin, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.